Фармакоэкономическое бремя статинов в лечении острого коронарног о синдрома и стабильной стенокардии

Abstract

There is a significant number of registered statins (brands and generics) in Belarus (lovastatin, atorvastatin simvastatin and rosuvastatin). Pharmacoeconomic studies of statins are topical because of the competition at the pharmaceutical market to ensure rational use of public and private funds. Overview of available statins has been conducted. "Cost of illness" has been calculated with the help of national clinical guidelines. Comparison of the each statin burden by determining the proportion of funds falling at each one in the overall cost of the patients care has been made. Cost of statins had no significant value in the overall "cost of illness" for acute coronary pathology. The cost of statins has a significant impact on the final ''cost of illness" in the case of chronic cardiac pathology. Pharmacoeconomic evaluation of statin choosing is important for prolonged use of medicines but not for short-term use in acute coronary syndrome.